

10/578449  
IAP20Rec'd PCT PTO 04 MAY 2006

Docket No.: 61959US(51580)  
(PATENT)

**IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)**  
**(National Phase of International Appln.: PCT/US04/036848**  
**Publication No. WO 2005/046587 A2)**

In re Patent Application of:  
Yow-Pin Lim, et al.

International Application No.: PCT/US04/036848

Confirmation No.: N/A

International Filing Date: November 5, 2004

Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

For: *PREPARATION AND COMPOSITION OF  
INTER-ALPHA INHIBITOR PROTEINS  
FROM HUMAN PLASMA FOR  
THERAPEUTIC USE*

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents which are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.M./

U.S. National Phase Application of  
PCT/US04/031412  
IDS

Attorney Docket No. 59755US(49949)

AP20 Rec'd CPTO 04 MAY 2006


previously been transmitted by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent application No. PCT/US04/036848 filed November 5, 2004. A copy of the International Search Report is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants submit that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61959US(51580). A duplicate copy of this paper is enclosed.

Dated: May 4, 2006

Respectfully submitted  
By   
Peter C. Lauro, Esq.  
Registration No.: 32,360  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorneys/Agents For Applicant

ACCEPTE D 04 MAY 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	Not Yet Assigned <b>449</b>
				Filing Date	Concurrently Herewith
				First Named Inventor	Yow-Pin Lim
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	61959US(51580)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> ( <i>if known</i> )	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			<sup>2</sup>
	CA**	HOFFER et al. Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration. Journal of Chromatography B, 1995, Vol. 669, pages 187-196, especially pages 187-190 and Figures 1-5.			
	CB**	LIM et al. Correlation between Mortality and the Levels of Inter-Alpha Inhibitors in Plasma of Patients with Severe Sepsis. The Journal of Infectious Diseases, 15 September 2003, Vol. 188, pages 919-926, especially pages 919, 920 and 925.			
	CC**	YANG et al. Administration of human inter-alpha-inhibitors maintains hemodynamic stability and improves survival during sepsis. Crit. Care. Med., 2002, Vol. 30, No. 3, pages 617-622, especially pages 617-621.			
	CD**	WU et al. Delayed administration of human inter-alpha inhibitor proteins reduces mortality in sepsis. Crit. Care. Med., 2004, Vol. 32, No. 8 pages 1747-1752, especially pages 1747-1751 and Figures 1-5.			
	CE**	LIM et al. Affinity purification and enzymatic cleavage of inter-alpha inhibitor proteins using antibody and elastase immobilized on CIM monolithic disks. Journal of Chromatography A, 2005, vol. 1065, pages 39-43.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Abdel Mohamed/	Date Considered	11/20/2009
--------------------	-----------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.M./